- US markets were closed in observance of Thanksgiving Day
- AstraZeneca (AZN.UK) reveals dosing mistake in COVID-19 vaccine trial
- Spread of the COVID-19 still accelerates in Europe
European indices finished today's session mixed amid thinner liquidity as US traders take a day off to celebrate Thanksgiving Day. ECB's minutes showed policymakers will likely launch more stimulus in December, although the decision to change current instruments was not unanimous. Meanwhile, German government decided to extend restrictive measures imposed early this month until December 20th as COVID-19 infection numbers remained high. On the economic data front, consumer morale in Germany and France figures came in below analysts' expectations challenging the idea of a quick return to normal in the euro zone's two biggest economies. Investors also digested a dosing error in AstraZeneca's (AZN.UK) potential coronavirus vaccine. Head of the White House’s vaccine task force expressed doubts about trial data and the vaccine's 90% effectiveness as group of patients was accidentally receiving a lower dose than intended. Company will likely run an additional global trial to evaluate the efficacy of its Covid-19 vaccine.
On the coronavirus front UK reported 18.2k new cases on Wednesday and 696 deaths, its highest figure since May 5th and France reported 16.3k new Covid-19 infections on Wednesday, the third consecutive daily increase. Germany reported over 22k new Covid-19 infections on Thursday, up from 18k on Wednesday and marking the fourth consecutive daily increase. Meanwhile US reported over 181K new COVID-19 infections yesterday, the 3rd highest on record.
Start investing today or test a free demo
Open real account TRY DEMO Download mobile app Download mobile appUS crude futures fell more than 1% to trade around $45.2 a barrel while the international benchmark Brent contract fell nearly 2% to trade around $47.7 a barrel. Elsewhere, gold futures rose slightly to $1809/oz, while silver reversed early gains to trade nearly flat around $23.3/oz amid slightly weaker dollar.
AstraZeneca (AZN.UK) stock has been trading in local sideways move. However, the price reached the support today - lower limit of consolidation range (77.67). If buyers manage to halt declines here, the upward move may be resumed. In such a scenario the nearest resistance to watch lies at 81.20 and is additionally strengthened by 200 SMA (red line). On the other hand, breaking below the aforementioned 77.67 handle may trigger a bigger downward move towards support at 71.58. Source: xStation5
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
